SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
"Alex Azar, the former U.S. president of drug giant Eli Lilly and Co. This would put the pharma industry in charge of regulating its own exorbitant prices and it seems likely that his private interests would swamp aspirations towards public service." (Photo: Worldwide Speakers Group)
With Trump's HHS Pick Big Pharma Takes Over Our Health System
A typical case of the revolving door of Washington, D.C.
Nov 14, 2017
Donald Trump announced his nominee to replace Tom Price for the nation's top health post.
His pick? Alex Azar, the former U.S. president of drug giant Eli Lilly and Co. This would put the pharma industry in charge of regulating its own exorbitant prices and it seems likely that his private interests would swamp aspirations towards public service.
A stroll through Azar's history would make him seem relatively innocuous -- he's a Yale educated lawyer who clerked for Antonin Scalia on the Supreme Court. During George W. Bush's presidency, he was general counsel and deputy assistant secretary of the Department of Health and Human Services under President George W. Bush.
Azar then left to become vice president and then president of Lilly USA, LLC. He's even been quoted saying that patients pay too much for prescription drugs, then going on to talk about the role of insurers, and prescription benefit managers contribute to how patients experience high drug prices.
His choice to join Eli Lilly's staff was questionable at the time, given that he had previously been an administrator overseeing investigations into the corporation's creation of marketing materials for unapproved use of one of their products.
In a typical case of the revolving door of Washington, D.C., Alex Azar left his post at HHS to take on leadership at one of the biggest pharmaceutical corporations in the country - one that is notorious for raising the price of it Insulin products by more than one thousand percent since 1994.
During Azar's tenure as vice president and president of Eli Lilly, the corporation increased the list price of Humalog insulin by 345 percent from just over $2,600 to more than $9,000. While price gouging consumers, the corporation spent millions to lobby Congress, the Department of Health and Human Services, and other administrative agencies -- $5.7 million in 2016 alone.
Eli Lilly is also named in a class action lawsuit which alleges that the corporation colluded with Novo Nordisk and Sanofi in order to keep the prices in the U.S. insulin market increasing over time. Much of the activity in the case occurred during Azar's time as the President of Eli Lilly USA.
Azar's statements on drug prices show a bias towards big pharma. When asked about drug prices at the Veeva Sumit on May 8, 2017, he avoided addressing price controls, limitations on high drug prices, or even admitting the prescription drug industry's role in setting high drug prices. He pivoted to the insurance industry as a culprit.
Azar has also called for lower barriers for regulation and safety of prescription drugs in multiple remarks, saying that regulators have set an "unrealistically high bar for new innovations to clear."
Public support for lowering drug prices is at an all-time high, with Americans from both major parties backing the idea to lower drug prices. Even Donald Trump has repeatedly called for reform, calling out prescription drug corporations for "getting away with murder."
The Trump administration's appointments for HHS secretary tell an entirely different story. Tom Price was riddled with scandal over investments made in pharmaceutical corporations while he was working on a trade agenda that directly benefited those corporations. After Price was ousted for unethical behavior, Trump has decided to double down on the influence of the industry by appointing a former drug corporation president to head the agency.
Azar's resume is full of experience both in the private and public sectors of health care and to some that resume may make him a more competent choice for HHS Secretary than his predecessor. Azar's major conflict of interest and previous statements suggest that he is not prepared to run the agency that could work towards the top issue for many Americans -- lowering drug prices.
Alex Azar's nomination to Health and Human Services undercuts the administration's message on lowering drug prices, and Senate should not confirm Azar to the role.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
© 2023 The Hill
Justin Mendoza
Justin Mendoza is the organizer for Public Citizen's Access to Medicines program, which works to challenge Big Pharma's economic and political power in the U.S. and abroad and was founded as a part of Public Citizen in 2010.
Donald Trump announced his nominee to replace Tom Price for the nation's top health post.
His pick? Alex Azar, the former U.S. president of drug giant Eli Lilly and Co. This would put the pharma industry in charge of regulating its own exorbitant prices and it seems likely that his private interests would swamp aspirations towards public service.
A stroll through Azar's history would make him seem relatively innocuous -- he's a Yale educated lawyer who clerked for Antonin Scalia on the Supreme Court. During George W. Bush's presidency, he was general counsel and deputy assistant secretary of the Department of Health and Human Services under President George W. Bush.
Azar then left to become vice president and then president of Lilly USA, LLC. He's even been quoted saying that patients pay too much for prescription drugs, then going on to talk about the role of insurers, and prescription benefit managers contribute to how patients experience high drug prices.
His choice to join Eli Lilly's staff was questionable at the time, given that he had previously been an administrator overseeing investigations into the corporation's creation of marketing materials for unapproved use of one of their products.
In a typical case of the revolving door of Washington, D.C., Alex Azar left his post at HHS to take on leadership at one of the biggest pharmaceutical corporations in the country - one that is notorious for raising the price of it Insulin products by more than one thousand percent since 1994.
During Azar's tenure as vice president and president of Eli Lilly, the corporation increased the list price of Humalog insulin by 345 percent from just over $2,600 to more than $9,000. While price gouging consumers, the corporation spent millions to lobby Congress, the Department of Health and Human Services, and other administrative agencies -- $5.7 million in 2016 alone.
Eli Lilly is also named in a class action lawsuit which alleges that the corporation colluded with Novo Nordisk and Sanofi in order to keep the prices in the U.S. insulin market increasing over time. Much of the activity in the case occurred during Azar's time as the President of Eli Lilly USA.
Azar's statements on drug prices show a bias towards big pharma. When asked about drug prices at the Veeva Sumit on May 8, 2017, he avoided addressing price controls, limitations on high drug prices, or even admitting the prescription drug industry's role in setting high drug prices. He pivoted to the insurance industry as a culprit.
Azar has also called for lower barriers for regulation and safety of prescription drugs in multiple remarks, saying that regulators have set an "unrealistically high bar for new innovations to clear."
Public support for lowering drug prices is at an all-time high, with Americans from both major parties backing the idea to lower drug prices. Even Donald Trump has repeatedly called for reform, calling out prescription drug corporations for "getting away with murder."
The Trump administration's appointments for HHS secretary tell an entirely different story. Tom Price was riddled with scandal over investments made in pharmaceutical corporations while he was working on a trade agenda that directly benefited those corporations. After Price was ousted for unethical behavior, Trump has decided to double down on the influence of the industry by appointing a former drug corporation president to head the agency.
Azar's resume is full of experience both in the private and public sectors of health care and to some that resume may make him a more competent choice for HHS Secretary than his predecessor. Azar's major conflict of interest and previous statements suggest that he is not prepared to run the agency that could work towards the top issue for many Americans -- lowering drug prices.
Alex Azar's nomination to Health and Human Services undercuts the administration's message on lowering drug prices, and Senate should not confirm Azar to the role.
Justin Mendoza
Justin Mendoza is the organizer for Public Citizen's Access to Medicines program, which works to challenge Big Pharma's economic and political power in the U.S. and abroad and was founded as a part of Public Citizen in 2010.
Donald Trump announced his nominee to replace Tom Price for the nation's top health post.
His pick? Alex Azar, the former U.S. president of drug giant Eli Lilly and Co. This would put the pharma industry in charge of regulating its own exorbitant prices and it seems likely that his private interests would swamp aspirations towards public service.
A stroll through Azar's history would make him seem relatively innocuous -- he's a Yale educated lawyer who clerked for Antonin Scalia on the Supreme Court. During George W. Bush's presidency, he was general counsel and deputy assistant secretary of the Department of Health and Human Services under President George W. Bush.
Azar then left to become vice president and then president of Lilly USA, LLC. He's even been quoted saying that patients pay too much for prescription drugs, then going on to talk about the role of insurers, and prescription benefit managers contribute to how patients experience high drug prices.
His choice to join Eli Lilly's staff was questionable at the time, given that he had previously been an administrator overseeing investigations into the corporation's creation of marketing materials for unapproved use of one of their products.
In a typical case of the revolving door of Washington, D.C., Alex Azar left his post at HHS to take on leadership at one of the biggest pharmaceutical corporations in the country - one that is notorious for raising the price of it Insulin products by more than one thousand percent since 1994.
During Azar's tenure as vice president and president of Eli Lilly, the corporation increased the list price of Humalog insulin by 345 percent from just over $2,600 to more than $9,000. While price gouging consumers, the corporation spent millions to lobby Congress, the Department of Health and Human Services, and other administrative agencies -- $5.7 million in 2016 alone.
Eli Lilly is also named in a class action lawsuit which alleges that the corporation colluded with Novo Nordisk and Sanofi in order to keep the prices in the U.S. insulin market increasing over time. Much of the activity in the case occurred during Azar's time as the President of Eli Lilly USA.
Azar's statements on drug prices show a bias towards big pharma. When asked about drug prices at the Veeva Sumit on May 8, 2017, he avoided addressing price controls, limitations on high drug prices, or even admitting the prescription drug industry's role in setting high drug prices. He pivoted to the insurance industry as a culprit.
Azar has also called for lower barriers for regulation and safety of prescription drugs in multiple remarks, saying that regulators have set an "unrealistically high bar for new innovations to clear."
Public support for lowering drug prices is at an all-time high, with Americans from both major parties backing the idea to lower drug prices. Even Donald Trump has repeatedly called for reform, calling out prescription drug corporations for "getting away with murder."
The Trump administration's appointments for HHS secretary tell an entirely different story. Tom Price was riddled with scandal over investments made in pharmaceutical corporations while he was working on a trade agenda that directly benefited those corporations. After Price was ousted for unethical behavior, Trump has decided to double down on the influence of the industry by appointing a former drug corporation president to head the agency.
Azar's resume is full of experience both in the private and public sectors of health care and to some that resume may make him a more competent choice for HHS Secretary than his predecessor. Azar's major conflict of interest and previous statements suggest that he is not prepared to run the agency that could work towards the top issue for many Americans -- lowering drug prices.
Alex Azar's nomination to Health and Human Services undercuts the administration's message on lowering drug prices, and Senate should not confirm Azar to the role.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.